Jon Leon
EVP & CFO at Owens & Minor
Again, remember that the $100,000,000 of Roadtec related outlays is included in the $38,000,000 of cash provided from operating activity, which obviously would have been significantly higher absent the termination of the Roadtec acquisition. This improvement in cash flow was due to a significant working capital reduction of nearly $94,000,000 in the quarter, driven by lower PNHS inventory levels compared to the first quarter and improved collection rates as a result of our enhanced revenue cycle operations in Patient Direct. Similar to the sleep journey, past and ongoing investments in our already best in class Patient Direct collection rate continue to pay off. The team has been very focused on working to sell the P and H business and have also been developing our outlook for the newly defined continuing operations for the remainder of 2025. As we think about the performance of continuing operations for the full year of 2025, we expect revenue of between $2,760,000,000 and $2,820,000,000 adjusted net income per share ranging from $1.02 to $1.07 and adjusted EBITDA range of $376,000,000 to $382,000,000 To assist with modeling, that would mean that through the 2025, revenue is expected to range from $1,400,000,000 to 1,460,000,000.00 adjusted net income from $0.47 to $0.52 per share and adjusted EBITDA from $183,000,000 to $189,000,000 Also, with the assumption that a sale of the P and H business is announced shortly, we would expect the profit path for the back half of the year to not reflect the typical seasonality of the Patient Direct business.